NEWS - MARKETING INITIATIVE
New Marketing Initiative Announced for Pain-Free Infant Jaundice Monitor
NEW YORK, Feb. 11 /PRNewswire/ -- Chromatics Color Sciences International, Inc. (Nasdaq: CCSI) confirmed today that its U.S. distribution partner Datex-Ohemda and its Ohmeda Medical Division is featuring CCSI's ColorMate(R) TLc-BiliTest(R) commercial products in a new marketing initiative to the home health care market.
Datex-Ohmeda recently announced the introduction of a "Continuing Care" initiative to bring enhanced customer service and quality products to healthcare providers and their patients in non-hospital settings -- initially offering products and services in two therapy areas -- Respiratory Care and Jaundice Management.
Datex-Ohmeda spotlighted the ColorMate(R)TLc-BiliTest(R)System in emphasizing the need for making available the latest technology to test and treat infant jaundice in home settings.
In making the announcement, Stuart Wildhorn, Director of Sales and Marketing for Datex-Ohmeda Continuing Care, said, "Patients are being discharged earlier than ever before. We recognize that nurses, respiratory therapists and other providers who care for patients outside the hospital are being asked to deliver increasingly higher levels of care. Our goal is to help these providers deliver quality care as efficiently and cost-effectively as possible."
Datex-Ohmeda further stated that the distribution and service capabilities of Datex-Ohmeda and Ohmeda Medical in these two areas are particularly well suited to meet the needs of care outside the hospital. Both companies have served the home care market for nearly a decade. According to Wildhorn, "Continuing Care provides customers with an exclusive focus on distribution outside the hospital backed by the healthcare resources of two global companies."
Chromatics Chief Executive Officer Darby Macfarlane said, "We are pleased to be featured in Datex-Ohmeda's and Ohmeda Medical's Continuing Care initiative. We have long recognized that, with earlier hospital discharges of newborns becoming so common, there would be a market for an accurate pain-free, non-invasive jaundice monitor to be used by home healthcare practitioners. This initiative launched by our premier medical distributor is an important milestone for all concerned."
Chromatics Color Sciences is in the business of color science and has developed technologies and intellectual properties that it believes have medical applications involving the detection and monitoring of certain chromogenic diseases or disorders such as hyperbilirubinemia in newborn infants. The Company defines chromogenic diseases or disorders as those diagnosed or monitored by the coloration of the human skin, tissue or fluid being affected. Additional medical applications to the monitoring of hyperbilirubinemia in newborns will require additional clinical trials and FDA clearances for commercial use.
The Company's technologies and intellectual properties also have other applications, including the scientific color measurement and classification of human skin, certain color-sensitive consumer products and in determining the color compatibility of such skin and product color classification for use in a variety of industries including the dental, cosmetics, beauty-aid and fashion industries.
Certain of the matters discussed in this announcement contain forward-looking statements.... |
